[20180316]LSB10009_更新时间：所有人都关注Allergan：制药公司史无前例的举动引发了对专利和药品法的质疑（上） .pdf

CRS INSIGHT Prepared for Members and Committees of Congress Legal SidebarLegal Sidebari i UPDATE: All Eyes on Allergan: Drug Companys Unprecedented Move Raises Questions for Patent and Drug Law (Part I) Updated March 16, 2018 UPDATE 2, 3/16/2018: On February 23, 2018, the Patent Trial and Appeal Board (PTAB) denied the Saint Regis Mohawk Tribes motion to terminate the inter partes proceedings based on tribal sovereign immunity, holding (1) the doctrine of tribal sovereign does not apply to PTAB proceedings and (2) the proceedings could continue “without the Tribes participation in view of Allergans retained ownership interests in the challenged patents.” Appeals have been filed with the U.S. Court of Appeals for the Federal Circuit with respect to both (1) the U.S. District Court for the Eastern District of Texass decision invalidating the Restasis Patents (discussed in UPDATE 1 below) and (2) the PTABs denial of the motion to terminate (Federal Circuit docket numbers 18-1130 and 18-1638, respectively). UPDATE 1, 10/19/2017: In the latest development in a series of events that has surprised many, on October 16, 2017, the U.S. District Court for the Eastern District of Texas issued